Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
KALV - KalVista Pharmaceuticals, Inc.
Market Cap 369.72M P/E - EPS this Y 0.90% Ern Qtrly Grth -
Income -141.77M Forward P/E -4.37 EPS next Y 54.00% 50D Avg Chg 11.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 41.00%
Dividend N/A Price/Book 2.29 EPS next 5Y - 52W High Chg -37.00%
Recommedations 1.60 Quick Ratio 8.33 Shares Outstanding 43.22M 52W Low Chg 162.00%
Insider Own 1.44% ROA -53.94% Shares Float 26.08M Beta 0.90
Inst Own 120.43% ROE -90.84% Shares Shorted/Prior 5.72M/5.68M Price 10.80
Gross Margin - Profit Margin - Avg. Volume 175,453 Target Price 30.17
Oper. Margin - Earnings Date Dec 5 Volume 302,251 Change 1.31%
Healthcare | Biotechnology | United States
About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

KalVista Pharmaceuticals, Inc. News
12/18/24 Sector Update: Health Care Stocks Advance in Afternoon Trading
12/18/24 KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says
12/16/24 KalVista Appoints Jeb Ledell as Chief Operating Officer
12/05/24 KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
12/04/24 KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/26/24 KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors
11/12/24 KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
11/05/24 KalVista Secures $184M Financing for Sebetralstat Launch
11/04/24 DRI Healthcare Trust Acquires Royalty Stake in Global Sales of Sebetralstat
11/04/24 KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
11/04/24 KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
10/28/24 KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology
10/18/24 KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
10/04/24 KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum
10/02/24 High Growth Tech Stocks To Watch In The United States
09/30/24 KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema
09/26/24 KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)
09/10/24 KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
09/10/24 KalVista Appoints Brian Piekos as Chief Financial Officer
09/06/24 KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Crockett Thomas Andrew CEO CEO Feb 01 Sell 16.49 10,000 164,900 117,532 02/05/24
Venrock Healthcare Capital Par... Director Director Jan 30 Buy 14.47 88,099 1,274,793 4,738,683 02/01/24
Venrock Healthcare Capital Par... Director Director Jan 25 Buy 13.31 91,804 1,221,911 4,650,584 01/29/24
Venrock Healthcare Capital Par... Director Director Jan 22 Buy 12.51 99,129 1,240,104 4,558,780 01/24/24
Venrock Healthcare Capital Par... 10% Owner 10% Owner Jan 17 Buy 12.51 143,605 1,796,499 4,459,651 01/19/24
Venrock Healthcare Capital Par... 10% Owner 10% Owner Jan 11 Buy 12.71 26,246 333,587 4,316,046 01/16/24
Venrock Healthcare Capital Par... 10% Owner 10% Owner Jan 08 Buy 12.56 137,700 1,729,512 4,289,800 01/10/24
Feener Edward P. Chief Scientific Off.. Chief Scientific Officer Jan 08 Sell 13 17,321 225,173 62,507 01/10/24
Venrock Healthcare Capital Par... 10% Owner 10% Owner Dec 27 Buy 12.32 519,017 6,394,289 4,092,731 12/29/23
Audhya Paul K. Chief Medical Office.. Chief Medical Officer Nov 17 Sell 8.23 7,985 65,717 36,568 11/21/23
Feener Edward P. Chief Scientific Off.. Chief Scientific Officer Nov 17 Sell 8.23 4,958 40,804 79,828 11/21/23
Yea Christopher Chief Development Of.. Chief Development Officer Nov 17 Sell 8.23 7,113 58,540 46,046 11/21/23
Audhya Paul K. Chief Medical Office.. Chief Medical Officer Aug 17 Sell 10.73 8,020 86,055 26,023 08/21/23
Feener Edward P. Chief Scientific Off.. Chief Scientific Officer Aug 17 Sell 10.73 4,976 53,392 73,289 08/21/23
Yea Christopher Chief Development Of.. Chief Development Officer Aug 17 Sell 10.73 7,142 76,634 41,662 08/21/23
Palleiko Benjamin L President, CFO, CBO.. President, CFO, CBO & Sec'y Aug 17 Sell 10.73 13,067 140,209 95,254 08/21/23
Crockett Thomas Andrew CEO CEO Aug 17 Sell 10.73 14,876 159,619 146,756 08/21/23
Yea Christopher Chief Development Of.. Chief Development Officer Jan 11 Sell 10.14 2,604 26,405 37,310 05/19/23
Palleiko Benjamin L President, CFO, CBO.. President, CFO, CBO & Sec'y Jan 11 Sell 10.14 4,037 40,935 78,126 05/19/23
Feener Edward P. Chief Scientific Off.. Chief Scientific Officer Jan 11 Sell 10.14 1,786 18,110 66,771 05/19/23
Crockett Thomas Andrew CEO CEO Jan 11 Sell 10.14 5,627 57,058 128,050 05/19/23
Audhya Paul K. Chief Medical Office.. Chief Medical Officer Jan 11 Sell 10.14 2,780 28,189 13,014 05/19/23
Audhya Paul K. Chief Medical Office.. Chief Medical Officer Aug 17 Sell 14.96 725 10,846 1,693 08/19/22
Feener Edward P. Chief Scientific Off.. Chief Scientific Officer Aug 17 Sell 14.96 532 7,959 61,132 08/19/22
Yea Christopher Chief Development Of.. Chief Development Officer Aug 17 Sell 14.96 1,145 17,129 33,597 08/19/22
Palleiko Benjamin L CFO, CBO & Secretary CFO, CBO & Secretary Aug 17 Sell 14.96 725 10,846 66,693 08/19/22
Crockett Thomas Andrew CEO CEO Aug 17 Sell 14.96 1,797 26,883 112,178 08/19/22
Crockett Thomas Andrew CEO CEO Mar 09 Sell 17.0693 10,000 170,693 114,670 03/11/22